Literature DB >> 19225886

Expression of resistin-like molecule beta in Barrett's esophagus: a novel biomarker for metaplastic epithelium.

Liduan Zheng1, Qiangsong Tong, Mixia Weng, Jun He, Qing Lv, Zehua Wu, Zhiyong Du, Hong Mei, Xiaohua Hou.   

Abstract

The formation of goblet cells characterizes the intestinal metaplasia of Barrett's esophagus (BE). Hematoxylin-eosin (HE) staining may fail to show intestinal metaplasia in BE, and PAS-Alcian Blue may present difficulties of interpretation due to its more heterogeneous staining. Recent evidence indicates that expression of resistin-like molecule beta (RELMbeta), a goblet cell-specific protein, is uniquely restricted to intestinal epithelium. However, it still remains largely unknown whether RELMbeta can be served as a biomarker for metaplastic epithelium of BE. In this study, 104 biopsy specimens of the distal esophagus from 88 suspected BE patients were collected, including 56 suspected intestinal metaplasia, 26 gastric type mucosa, and 22 squamous epithelium. We evaluated the RELMbeta expression in these biopsy specimens, and compared with those of CDX-2 immunostaining and PAS-Alcian Blue staining (pH 2.5). Of the suspected intestinal metaplasia specimens, 46 presented intestinal-type goblet cells and were immunostaining positive for RELMbeta and CDX-2, the remaining ten possessed only goblet cell mimickers and were not reactive with RELMbeta and CDX-2. Of the gastric-type mucosa specimens, none reacted with either RELMbeta or CDX-2. Moreover, the squamous epithelium was not reactive with RELMbeta and CDX-2. Acid mucin was present in goblet cells in all cases of BE and columnar cells in ten gastric specimens. In addition, the reactivity of RELMbeta was enhanced in six BE specimens with dysplasia. These results provide evidence that RELMbeta protein may be a novel biomarker to distinguish the intestinal-type goblet cells and goblet cell mimickers, and useful in the correct diagnosis of BE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225886     DOI: 10.1007/s10620-009-0719-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  The lower esophagus lined by columnar epithelium.

Authors:  N R BARRETT
Journal:  Surgery       Date:  1957-06       Impact factor: 3.982

2.  Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia.

Authors:  Mamoun Younes; Atilla Ertan; Gulchin Ergun; Ray Verm; Margaret Bridges; Karen Woods; Frank Meriano; A Carl Schmulen; Ronald Colman; Craig Johnson; Alberto Barroso; Jim Schwartz; John McKechnie; Juan Lechago
Journal:  Arch Pathol Lab Med       Date:  2007-04       Impact factor: 5.534

3.  Chronic peptic ulcer of the oesophagus and 'oesophagitis'.

Authors:  N R BARRETT
Journal:  Br J Surg       Date:  1950-10       Impact factor: 6.939

4.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology.

Authors:  R E Sampliner
Journal:  Am J Gastroenterol       Date:  1998-07       Impact factor: 10.864

5.  Morphology of the epithelium of the distal esophagus in patients with midesophageal peptic strictures.

Authors:  J S Trier
Journal:  Gastroenterology       Date:  1970-04       Impact factor: 22.682

6.  Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus.

Authors:  S C Burjonrappa; S Reddimasu; Z Nawaz; X Gao; P Sharma; B Loggie
Journal:  Indian J Cancer       Date:  2007 Jan-Mar       Impact factor: 1.224

7.  Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study.

Authors:  G S Arul; M Moorghen; N Myerscough; D A Alderson; R D Spicer; A P Corfield
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

8.  Regulation of RELM/FIZZ isoform expression by Cdx2 in response to innate and adaptive immune stimulation in the intestine.

Authors:  Mei-Lun Wang; Marcus E Shin; Pamela A Knight; David Artis; Debra G Silberg; Eunran Suh; Gary D Wu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-12-02       Impact factor: 4.052

9.  The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory zone 1/resistin-like molecule alpha gene expression by a STAT6 and CCAAT/enhancer-binding protein-dependent mechanism.

Authors:  Adrian M Stütz; Louise A Pickart; Alexandre Trifilieff; Thomas Baumruker; Eva Prieschl-Strassmayr; Maximilian Woisetschläger
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

10.  Barrett's esophagus. Comparison of benign and malignant cases.

Authors:  D B Skinner; B C Walther; R H Riddell; H Schmidt; C Iascone; T R DeMeester
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

View more
  5 in total

1.  Plasma levels of resistin-like molecule beta in humans.

Authors:  Andrew P Neilson; Zora Djuric; Susan Land; Ikuko Kato
Journal:  Cancer Epidemiol       Date:  2010-11-19       Impact factor: 2.984

2.  Helicobacter pylori Infection Facilitates the Expression of Resistin-like Molecule Beta in Gastric Carcinoma and Precursor Lesions.

Authors:  Hong-Jun Li; Er-Hu Fang; Jian-Qun Wang; Li-Duan Zheng; Qiang-Song Tong
Journal:  Curr Med Sci       Date:  2020-03-13

3.  Effects of resistin-like molecule β over-expression on gastric cancer cells in vitro.

Authors:  Li-Duan Zheng; Chun-Lei Yang; Teng Qi; Meng Qi; Ling Tong; Qiang-Song Tong
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

4.  Hepatocyte paraffin 1 antigen as a biomarker for early diagnosis of Barrett esophagus.

Authors:  Jennifer A Jeung; Justin J Coran; Chen Liu; Diana M Cardona
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

5.  Expression of resistin-like molecule beta in gastric cancer: its relationship with clinicopathological parameters and prognosis.

Authors:  Liduan Zheng; Mixia Weng; Jun He; Xiuping Yang; Guosong Jiang; Qiangsong Tong
Journal:  Virchows Arch       Date:  2009-12-05       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.